← Eichor
Study identifier: NCT07322627 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

ALDH2 Single Nucleotide Polymorphisms and Prognosis of Esophageal Cancer Patients

Condition: Esophageal Cancer  ·  Sponsor: National Taiwan University Hospital

PhaseN/A
Planned participants700
Who can joinMale, 18 Years to 99 Years
Healthy volunteersNo

About this study

Alcohol consumption, smoking, and betel nut chewing have been proven to be closely associated with the risk of esophageal cancer (EC). Recent studies have shown that alcohol-related detoxification genes in the ALDH family influence individual susceptibility to esophageal cancer. Aldehyde dehydrogenase 2 (ALDH2) is one of the most important enzymes in the ALDH family, involved in the metabolism of alcohol, acetaldehyde, and environmental aldehydes in the human body. We hypothesize that functional variations in ALDH2 may have a significant impact on the survival of esophageal cancer patients. This study aims to investigate the correlation between ALDH2 gene polymorphism and the survival of esophageal cancer patients.

This description comes directly from the study's public registry record.

Talk to the study team

Jang-Ming Lee  ·  +886223123456  ·  jmlee@ntu.edu.tw

Always discuss trial participation with your own doctor first.

Locations (1)

National Taiwan University HospitalTaipei, TaiwanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07322627